Stryker Corporation $SYK Shares Bought by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in Stryker Corporation (NYSE:SYK) by 7.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 84,355 shares of the medical technology company’s stock after acquiring an additional 5,819 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Stryker were worth $33,373,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Consolidated Portfolio Review Corp grew its stake in shares of Stryker by 4.2% during the 2nd quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock valued at $256,000 after buying an additional 26 shares during the period. Princeton Global Asset Management LLC boosted its holdings in Stryker by 16.9% in the second quarter. Princeton Global Asset Management LLC now owns 180 shares of the medical technology company’s stock valued at $71,000 after acquiring an additional 26 shares during the last quarter. Sunflower Bank N.A. grew its position in Stryker by 4.0% during the second quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock valued at $275,000 after acquiring an additional 27 shares during the period. Pitti Group Wealth Management LLC increased its stake in Stryker by 3.2% during the second quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock worth $341,000 after acquiring an additional 27 shares during the last quarter. Finally, Sachetta LLC raised its holdings in shares of Stryker by 58.7% in the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 27 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

NYSE:SYK opened at $362.39 on Friday. The firm has a 50-day moving average of $371.96 and a two-hundred day moving average of $381.22. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The stock has a market cap of $138.59 billion, a P/E ratio of 48.00, a PEG ratio of 2.66 and a beta of 0.94. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, topping the consensus estimate of $3.13 by $0.06. The business had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, research analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of the stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the transaction, the director directly owned 2,702,108 shares in the company, valued at $954,600,714.24. This represents a 9.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 520,500 shares of company stock valued at $184,803,065. Company insiders own 5.90% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on SYK. Truist Financial increased their target price on shares of Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a research report on Friday. Rothschild Redb raised shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. BTIG Research reissued a “buy” rating and issued a $410.00 target price on shares of Stryker in a research note on Friday. Evercore ISI lowered their price target on Stryker from $410.00 to $405.00 and set an “outperform” rating for the company in a report on Friday, October 31st. Finally, Barclays raised their price objective on Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research report on Wednesday, October 22nd. Thirteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $434.37.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.